AI assistant
Vanda Pharmaceuticals Inc. — Director's Dealing 2021
Dec 2, 2021
33390_dirs_2021-12-02_48b2b85b-0c44-4459-865c-a43e9504dc4f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Vanda Pharmaceuticals Inc. (VNDA)
CIK: 0001347178
Period of Report: 2021-11-30
Reporting Person: Polymeropoulos Mihael Hristos (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-30 | Common Stock | M | 78324 | $4.88 | Acquired | 1299386 | Direct |
| 2021-11-30 | Common Stock | S | 50000 | $16.4855 | Disposed | 1249386 | Direct |
| 2021-12-01 | Common Stock | M | 71676 | $4.88 | Acquired | 1321062 | Direct |
| 2021-12-01 | Common Stock | S | 46200 | $16.0032 | Disposed | 1274862 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-30 | Employee Stock Option (Right to Buy) | $4.88 | M | 78324 | Disposed | 2021-12-05 | Common Stock (78324) | Direct |
| 2021-12-01 | Employee Stock Option (Right to Buy) | $4.88 | M | 71676 | Disposed | 2021-12-05 | Common Stock (71676) | Direct |
Footnotes
F1: Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 5, 2021 as reflected in this Form 4.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.10 to $16.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.70 to $16.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4: The option vested in 48 equal monthly installments beginning on January 6, 2012.